1
Securities and Exchange Commission
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 6, 1997
Biogen, Inc.
(Exact name of Registrant as specified in its charter)
Massachusetts 0-12042 04-3002117
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
14 Cambridge Center
Cambridge, MA 02142
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 679-2000
2
Item 5. Other Events.
On October 6, 1997, the Registrant publicly disseminated a press
release announcing the authorization by the Registrant's Board of Directors of
the repurchase by the Registrant of up to 2,500,000 shares of the Registrant's
Common Stock. The Registrant expects that the stock repurchases will commence in
the near term and will occur from time to time over the next two years. The
stock repurchase program may be discontinued at any time. The information
contained in the press release is incorporated herein by reference and filed as
Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
99.1 The Registrant's Press Release dated October 6, 1997.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Biogen, Inc.
By: /s/ Michael J. Astrue
------------------------------------
Michael J. Astrue
Vice President - General Counsel
Date: October 6, 1997
4
EXHIBIT INDEX
Exhibit
Number Description
99.1 The Registrant's Press Release
dated October 6, 1997